期刊文献+

芬太尼透皮贴剂联合唑来膦酸治疗多发性骨转移疼痛的疗效观察 被引量:5

下载PDF
导出
摘要 骨骼是晚期恶性肿瘤最常见的转移和受累部位,全球每年有超过150万恶性肿瘤患者发生骨转移,常导致骨疼痛、病理性骨折,脊髓压迫及高钙血症等骨相关事件,严重干扰了患者生活质量。芬太尼透皮贴剂(商品名:多瑞吉)是新型的阿片类镇痛药,具有镇痛效果好,不良反应低,使用方便,作用持久等特点,在临床上广泛应用。唑来磷酸通过抑制因破骨活性增加而导致的骨吸收,可减少骨转移引起骨疼痛等骨相关事件的发生率。
作者 周艳 芦珊
机构地区 江西省肿瘤医院
出处 《实用癌症杂志》 2009年第6期658-659,共2页 The Practical Journal of Cancer
  • 相关文献

参考文献6

二级参考文献14

  • 1汪楣 谷铣之 等.骨转移.放射肿瘤学[M].北京:北京医科大学中国协和医科大学出版社,1993.816-817.
  • 2孙燕,癌症三阶梯止痛指导原则,1999年,115页
  • 3汪楣,放射肿瘤学,1993年,816页
  • 4蒙法迪尼,成人与儿童肿瘤内科手册,1988年,31页
  • 5Neville-Webbe H,Coleman RE,et al.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliat Med,2003,17(6):539-553.
  • 6Matsumoto S,Kimura S,Segawa H,et al.Efficacy of the third-generation bisphosphonate,zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines[J].Lung Cancer,2005,47(1):31-39.
  • 7Chen T,Berenson J,Vescio R,et al.Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases[J].J Clin Pharmacol,2002,42(11):1228-1236.
  • 8Rosen LS,Gordon D,Tchekmedyian NS,et al.Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors:a randomized,Phase III,double-blind,placebo-controlled trial[J].Cancer,2004,100 (12):2613-2621.
  • 9Kraj M,Poglod R,Maj S,et al.Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience)[J].Acta Pol Pharm,2002,59(6):478-482.
  • 10Berenson J,Hirschberg R.Safety and convenience of a 15-minute infusion of zoledronic acid[J].Oncologist,2004,9(3):319-329.

共引文献278

同被引文献41

  • 1范向辉,段玉龙,史中州,丁照黎,刘桂玲.放射治疗骨转移癌疼痛63例临床分析[J].现代肿瘤医学,2006,14(11):1437-1438. 被引量:6
  • 2Shimony JS, Gilula LA, Zeller AJ, et al. Percutaneous vertebroplasty formalignant comp ression fractures with epidural involvement[J] Radiology,2004,232:846-853.
  • 3Bickels J,Dadia S,Lidar Z.Surgical management of metastatic bone disease[J].J Bone Joint Surg Am,2009,91(6):1503-1516.
  • 4Van Seventer R,Smit JM,Schipper RM,et a1.Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain[J].Curr Med Res Opin,2003,19(6):457-659.
  • 5Marier JF,Lor M,Morin J,et al.Comarative bioequivlaence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation[J].Br J Clin Pharmacol,2007,63(1):121-124.
  • 6Marier JF,Lor M,Potivn D,et al.Pharmacokinetics,tolerability,and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects[J].J Clinical Pharmacology,2006,46(6):642-653.
  • 7Croucher P,Jagdev S,Coleman R.The anti-tumor potential of zoledronic acid[J].Breast Cancer,2003,12(2):30-36.
  • 8Welligton K,Goa KL.Zoledronic acid:a review of its use in the management of bone metastases and hypercalcaemis of malignancy[J].Durgs,2003,63(4):417-437.
  • 9Weinfurt KP,Castel LD,Li Y,et a1.Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions[J].Med Care,2004,42(2):164-175.
  • 10Kunzmann V,Bauer E,Feurle J,et al.Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma[J].Blood,2000,96(2):384-392.

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部